Capitol Vein Blog

Wednesday, November 27, 2013

New Varicose Vein Treatment Now FDA Approved


As a clinical investigator for VarithenaTM, I am happy to announce that BTG plc has received approval from the US Food and Drug Administration (FDA) to market its new varicose vein treatment. This new medication uses injectable foam to close refluxing veins, which are the source of varicose veins in the leg. Currently the "gold standard" treatment for saphenous vein reflux is thermal ablation.  VNUS Closure, the most studied technique to achieve this goal, is highly successful in relieving the symptoms of aching, pain, swelling and preventing blood clots.

Varithena allows us to use a small needle though which we inject a special medication that achieves the same end result as VNUS Closure, though without using as much local anesthesia. The treatment results thus far are very good and I anticipate that, over time, Varithena will become a very popular option for doctors and patients.

Once the product is released, we’ll be able to offer this treatment to our patients.  We’ll keep you posted!  To read the full press release from BTG plc, click here.

0 comments :

Post a Comment